Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2000
10/05/2000WO2000058292A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
10/05/2000WO2000058291A1 Pesticidal enantiomer-pure 2,4-disubstituted oxazolines
10/05/2000WO2000058285A1 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
10/05/2000WO2000058281A1 Substrates for thioredoxin reductase
10/05/2000WO2000058279A1 Diaryl derivatives and their use as medicaments
10/05/2000WO2000058271A1 Nitrogen mustard compounds and prodrugs therefor
10/05/2000WO2000058270A2 Hsv primase inhibitors
10/05/2000WO2000057922A1 Intramyocardial injection of autologous bone marrow
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057918A2 Novel formulations comprising lipid-regulating agents
10/05/2000WO2000057916A1 Sphingomyelin containing preparation for the enhancement of tumor therapy
10/05/2000WO2000057913A1 Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
10/05/2000WO2000057905A1 Recombinant neospora antigens and their uses
10/05/2000WO2000057900A2 Factor for regulation of neurite growth
10/05/2000WO2000057899A1 Thrombospondin-2 and uses thereof
10/05/2000WO2000057898A1 Compositions for reducing blood cholesterol
10/05/2000WO2000057894A1 Use of valeriana for the treatment of restless leg syndrome and related disorders
10/05/2000WO2000057892A1 Use of a serenoa repens extract for the production of a medicament to treat prostate cancer
10/05/2000WO2000057890A1 Pulmonary delivery of protonated/acidified nucleic acids
10/05/2000WO2000057889A1 Skin preparations for external use
10/05/2000WO2000057888A1 Compositions for preventing and treating type i allergy
10/05/2000WO2000057886A1 Dispersible macrolide compounds and method for the production thereof
10/05/2000WO2000057885A1 Pharmaceutical emulsions for retroviral protease inhibitors
10/05/2000WO2000057884A1 Medicinal preparation containing at least in part acetylsalicylic acid as active ingredient
10/05/2000WO2000057883A1 Use of vasopeptidase inhibitors to treat angina pectoris
10/05/2000WO2000057882A1 Concomitant drugs for preventing or treating infection with gram-positive bacteria
10/05/2000WO2000057881A1 Cilostazol preparation
10/05/2000WO2000057880A1 Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
10/05/2000WO2000057879A1 Treatment of brain changes with myelin protective agents
10/05/2000WO2000057878A1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment
10/05/2000WO2000057877A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
10/05/2000WO2000057876A1 Novel antioxidant formulations and methods for using them
10/05/2000WO2000057875A1 Compositions containing tea catechins as cancer specific proliferation inhibitors
10/05/2000WO2000057874A1 A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
10/05/2000WO2000057873A2 Granulate with high content of l-carnitine or an alkanoyl l-carnitine
10/05/2000WO2000057872A1 Z-styryl sulfone anticancer agents
10/05/2000WO2000057871A2 Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
10/05/2000WO2000057870A2 Viral treatment
10/05/2000WO2000057869A2 Viral treatment
10/05/2000WO2000057868A2 Use of carbamamic acid derivatives for the treatment of viral infections
10/05/2000WO2000057867A2 Improved cancer treatment with temozolomide
10/05/2000WO2000057866A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections
10/05/2000WO2000057865A2 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
10/05/2000WO2000057864A2 Cyclic glycerophosphates and analogs thereof
10/05/2000WO2000057863A2 Use of pyridoxine compounds for treatment of cardiovascular and related pathologies
10/05/2000WO2000057862A2 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases
10/05/2000WO2000057861A2 Use of cytidine derivatives for the treatment of leukaemia
10/05/2000WO2000057860A2 Peroxovanadium compounds as antineoplastic agents for the treatment of cancer
10/05/2000WO2000057859A1 Novel formulations comprising lipid-regulating agents
10/05/2000WO2000057858A1 Sublingual buccal effervescent
10/05/2000WO2000057857A1 Rapidly disintegrable tablet for oral administration
10/05/2000WO2000057853A2 Pharmaceutical composition containing an extrusion additive
10/05/2000WO2000057852A2 Methods and compositions for treating solid tumors
10/05/2000WO2000057851A2 High potency dihydroergotamine compositions
10/05/2000WO2000057840A2 Dermatological topical composition
10/05/2000WO2000057837A2 Compositions and methods for effecting the levels of cholesterol
10/05/2000WO2000057836A2 Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of cd44 membrane receptors of skin cells
10/05/2000WO2000057824A1 Transdermal therapeutic system with nicotine and addition of monoterpene ketones
10/05/2000WO2000057727A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions
10/05/2000WO2000057720A1 Method for selectively altering body fat level, feed efficiency, or weight gain
10/05/2000WO2000057719A1 Additives for crustacean or fish feeds and feeds
10/05/2000WO2000057701A1 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
10/05/2000WO2000057699A1 Oral anti-odor compositions
10/05/2000WO2000042026B1 Non-peptide glp-1 agonists
10/05/2000WO2000040217B1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids
10/05/2000WO2000032178A3 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
10/05/2000WO2000032171A3 Autoahesive oral transmucosal delivery dosage form
10/05/2000WO2000031133A3 Potassium channel interactors and uses therefor
10/05/2000WO2000031127A3 Protein fragments for use in protein targeting
10/05/2000WO2000030625A3 Use of phosphonoformic acid derivatives for treating infections
10/05/2000WO2000030624A3 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
10/05/2000WO2000026379A3 Polypeptide mediating cell permeability
10/05/2000WO2000026225A3 Nucleosides with anti-hepatitis b virus activity
10/05/2000WO2000020625A9 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
10/05/2000WO2000016765A9 Method and composition for treatment of inflammatory bowel disease
10/05/2000WO2000004901A9 Small molecule inhibitors of bcl-2 proteins
10/05/2000WO2000001716A3 Vasculoprotector
10/05/2000WO1998041232A3 Compositions for modulating responsiveness to corticosteroids
10/05/2000DE19916383A1 Pharmazeutische Zusammensetzung mit einem Extrusionsstoff A pharmaceutical composition comprising an extrusion material
10/05/2000DE19915576A1 New equilenine derivatives, useful as antioxidative estrogenic hormonal steroids for e.g. prophylactic geriatrics in women and men
10/05/2000DE19915102A1 Treatment of cellular damage and disorders caused by reactive oxygen species e.g. atherosclerosis, ischemias or schizophrenia, by administration of limonene or oil containing it
10/05/2000DE19914621A1 Stable aqueous solution of the thalidomide derivative EM 12 for parenteral administration in isotonic glucose solution has a specified pH, useful for treating immunological, hematologic and oncologic diseases
10/05/2000DE19913534A1 Avermectinderivate Avermectin derivatives
10/05/2000DE19909373A1 Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung New PNA monomers, resulting PNA oligomers and their use
10/05/2000DE19908483A1 Substances that inhibit cellular nicotinamide mononucleotide formation, useful for cancer therapy and immunosuppression
10/05/2000CA2707691A1 Sphingomyelin containing preparation
10/05/2000CA2383592A1 2384891 acids including open reading frames encoding polypeptides; orfx
10/05/2000CA2370441A1 50 human secreted proteins
10/05/2000CA2369009A1 Factor for regulation of neurite growth
10/05/2000CA2368927A1 45 human secreted proteins
10/05/2000CA2368909A1 48 human secreted proteins
10/05/2000CA2368880A1 Dispersible macrolide compounds and method for the production thereof
10/05/2000CA2368700A1 49 human secreted proteins
10/05/2000CA2368658A1 A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
10/05/2000CA2368657A1 Thrombospondin-2 and uses thereof
10/05/2000CA2368647A1 Viral treatment
10/05/2000CA2368631A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
10/05/2000CA2368616A1 Use of vasopeptidase inhibitors to treat angina pectoris
10/05/2000CA2368597A1 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
10/05/2000CA2368587A1 High potency dihydroergotamine compositions
1 ... 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 6245 6246 6247 6248 6249 6250 6251 6252 6253 ... 7860